This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
Some lists ban BPC-157 and other peptides as performance drugs
Horska A et al
The volume drawn determines the final concentration (see dilution charts below)
It wont stop hair completely, but it can make regrowth finer and less noticeable over time
Pharmacists should be aware of the following side effects to properly advise and help patients manage accordingly: Hypoglycaemia consider dose reduction of concomitant medications, particularly sulfonylurea and insulin, to prevent hypoglycaemia if this a concern